Orchid Pharma Limited — Others, 25-01-2025: Certificate under SEBI (Depositories and Participants) Regulations, 2018

Orchid Pharma has announced a board meeting to review the Reconciliation of Share Capital Audit Report for the quarter ended December 31, 2024. The report confirms that the total issued capital remains at 5,07,19,105 shares, with 79.16% held in dematerialized form, indicating strong investor participation. The register of members is updated, and there are no pending demat requests beyond the usual timeframes, which reflects effective management of share capital. This update could enhance investor confidence by showing transparency and compliance in capital management, providing a positive outlook for the company's governance practices.